|
Ling
Li, Department of Clinical Biochemistry, Chongqing Medical
University, Chongqing 400016, China
Gang-Yi Yang, Department of Endocrinology, The Second
Affiliated Hospital, Chongqing Medical University, Chongqing 400010,
China
Supported by the National Natural Science Foundation of
China, No. 30270631, No. 30370671, Science Foundation of Chongqing
Health Bureau, No. 99-3002 and Applied Basic Research Foundation of
Chongqing Science and Technology Committee, No. 02-34 and Science
Foundation of China Education Ministry, No. 2003-406
Correspondence to: Dr. Gang-Yi Yang, Department of
Endocrinology, The Second Affiliated Hospital, Chongqing Medical
University, Chongqing 400010, China.
yanggangyi@hotmail.com
Telephone: +86-23-68486115
Fax: +86-23-68486115
Received: 2003-11-18
Accepted: 2003-12-08
Abstract
AIM: To explore the influence of hepatic glucose production on
acute insulin resistance induced by a lipid infusion in awake rats.
METHODS: A hyperinsulinaemic-euglycaemic clamp was established in
awake chronically catheterized rats. Two groups of rats were studied
either with a 4-h intraarterial infusion of lipid/heparin or saline.
Insulin-mediated peripheral and hepatic glucose metabolism was
assessed by hyperinsulinaemic-euglycaemic clamp combined with [3-3H]-glucose
infusion.
RESULTS:
During hyperinsulinaemic-euglycaemic clamp, there was a significant
increase in plasma free fatty acid (FFA, from 741.9±50.6
to 2346.4±238.5
mmol/L,
P<0.01) in lipid-infused group. The glucose infusion rates
(GIR) in the lipid infusion rats, compared to control rats, were
significantly reduced (200-240 min average: lipid infusion; 12.6±1.5 vs control; 34.0±1.6 mg/kg.min, P<0.01), declining to - 35% of the
corresponding control values during the last time of the clamp (240
min: lipid infusion; 12.0±1.9
vs control; 34.7±1.7
mg/kg.min, P<0.0001). At the end of clamp study, the
hepatic glucose production (HGP) in control rats was significantly
suppressed (88%) from 19.0±4.5
(basal) to 2.3±0.9
mg/kg.min (P<0.01). The suppressive effect of insulin on
HGP was significantly blunted in the lipid-infused rats (200-240
min: from 18.7±3.0
to 23.2±3.1
mg/kg.min (P<0.05). The rate of glucose disappearance (GRd)
was a slight decrease in the lipid-infused rats compared with
controls during the clamp.
CONCLUSION:
These data suggest that lipid infusion could induces suppression of
hepatic glucose production, impairs the abilities of insulin to
suppress lipolysis and mediate glucose utilization in peripheral
tissue. Therefore, we conclude that lipid-infusion induces an acute
insulin resistance In vivo.
Li L, Yang GY. Effect
of hepatic glucose production on acute insulin resistance induced by
lipid-infusion in awake rats. World J Gastroenterol 2004; 10(21): 3208-3211
http://www.wjgnet.com/1007-9327/10/3208.asp
INTRODUCTION
Insulin resistance plays a primary role in the development of
type 2 diabetes and is a feature of other disorders including
obesity, dyslipidemias, hypertension, and cardiovascular disease[1].
The mechanism underlying the occurrence of insulin resistance is
unknown but may be related to alterations in lipid metabolism[2].
More than 30 years ago, Randle and colleagues demonstrated that free
fatty acids (FFA) competed with glucose for substrate oxidation in
isolated rat heart and diaphragm muscle preparations and speculated
that increased fat oxidation might cause insulin resistance
associated with diabetes and obesity[3,4]. Subsequently,
some studies have emphasized that, while an increase in circulating
FFA during insulin clamp studies could promptly decrease the rate of
carbohydrate oxidation, defective glucose uptake which could be
detected 3-4 h after lipid infusion in humans[5,6]. Roden
and Dresner have revealed that lipid/heparin infusions could
increase plasma FFA levels, inhibit whole-body glucose disposal
during hyper- and euglycemic-hyperinsulinemia and insulin-dependent
glucose uptake by human forearm tissues In vivo, and also
found that acute elevations in plasma fatty acids in humans resulted
in decreased glucose transport activity, as reflected by decreased
concentrations of intracellular glucose 6-phosphate and glucose[7,8].
Thus, it is possible that chronic elevation of endogenous FFAs
contributes to insulin resistance in many pathophysiologic
conditions in humans. Acute elevations in plasma FFA levels during a
triglyceride emulsion infusion have also been shown to impaire
insulin-mediated glucose uptake and to inhibit hepatic glucose
production (HGP) in rats[9].
In the current study, we used a
triglyceride and cholesterolester emulsion infusion in combination
with hyperinsulinemic-euglycemic clamps to assess the impact of
elevated FFA levels on HPG and overall insulin action.
MATERIALS
AND METHODS
Preparation of animals
A total of 24 Male Sprague-Dawley rats weighing 250-300 g were
housed in individual cages and subjected to an environmentally
controlled room with a 12-h light/dark cycle, where they had free
access to standard rat chow and water. Five to 7 d before the In
vivo study, rats were anesthetized with an intraperitoneal
injection of pentobarbital (50 mg/kg body mass). A silastic catheter
(I.D. = 0.02 in ) was inserted into the right internal jugular vein
and extended to the level of the right atrium. The catheter for
carotid artery was constructed with a short (25 mm) segment of
polyethylene tubing (PE-10), connected to a 10-cm length of PE-50 by
heating in a flame. The smaller end was advanced through the left
carotid artery until its tip reached the aortic arch. The free ends
of the catheters were attached to the long segments of steel tubing
and tunneled subcutaneously around the side to the back of the neck
where they were exteriorized through a skin incision and then
securely anchored to the skin by a standard wounded clip. At the end
of the procedure, catheters were flushed with 300 ?L isotonic saline
containing heparin (20 U/mL) and ampicillin (5 mg/mL) and then filled
with a viscous solution of heparin (300 U) and 800 g/L
polyvinylpyrollidone (PVP-10, Fisher, NJ) to prevent refluxing of
blood into the catheter lumen.
In
vivo clamp studies
Animals
were allowed at least five days to recover from the effects of
surgery. All studies were conducted in the morning following a 12 to
14-h overnight fast. Throughout the study, the rats were allowed to
move freely within the confines of a cage. One hour before clamping
the venous and arterial lines were filled with a 9 g/L NaCl solution
containing 10 IU/mL heparin. Three double lumen swivels, allowing
separate fluid infusions, were connected to three peristaltic pumps.
One arterial line was used for the infusion of a 250 g/L glucose
solution at a variable rate and the other line was used for infusion
of a mixture of (3-3H)-glucose (Amersham Inc, USA),
insulin and 150 mL/L lipid emulsion/heparin (20 U/mL). The venous
blood sampling tube allowed frequent sampling and repletion of blood
loss by means of fresh whole blood obtained from littermates.
At the start of euglycaemic clamp, continuous infusions of
isotonic saline (control group, n = 12) and lipid emulsion
with heparin (lipid group, n = 12) were maintained for 4 h at
a rate 1.5 mL/h during prolonged euglycemic-hyperinsulinemic clamp
studies. At t = 60 min, a bolus (6 mCi)
and continuous infusion (0.2 mCi/min
) of (3-3H) glucose were initiated and continued
throughout 3 h study. At t = 120 min, continuous infusions of
insulin (4.8 mU/kg.min) and 250 g/L glucose were maintained for 2 h,
250 g/L glucose was adjusted every 5-10 min, maintaining basal
plasma glucose concentrations (-5 mmol/L) during the insulin clamp
studies. At t = 0, 120, 200, 220, 230 and 240 min, blood
samples were collected for determination of plasma glucose, insulin,
free fatty acid (FFA) and specific activity of tritiated glucose.
A
separate set of 240 min lasting control clamp experiments without
lipid infusion were performed to investigate the self-amplifying
effect of long-term clamping on insulin-mediated glucose metabolism,
since was glucose metabolism was not constant during a 240 min study[10].
The experimental procedure was identical to the lipid infusion
clamps.
Analytical
procedures
Plasma insulin was measured by radioimmunoassay (RIA) using
rat insulin as standard (Linco Research, Inc. MO). Inter- and
intra-assay variations of the insulin assay were 5.8% and 6.5%,
respectively. Enzymatic colorimetric kits were used to determine
plasma concentration of FFA ( Wako Chemicals, Inc. VA). The inter-
and intra-assay variations were 3.6% and 4.2%, respectively, during
measurement of plasma FFA. Plasma for [3-3H]-glucose
radioactivity (150 mL)
was deproteinized by barium hydroxide-zinc sulphate, the supernatant
was evaporated to dryness at 60 °C to eliminate tritiated water and counted for 10 min in a beta
scintillation counter.
Calculations
The rate of exogenous infused glucose to maintain
euglycaemia during the steady-state period (from t = 180-240
min) was used for the assessment of insulin action. All calculations
were carried out in this period when the total amount of glucose
taken up by all tissues of the body was equal to the input of
glucose into the body. During this steady-state, when the rate of
glucose appearance (GRa) was equal to the rate of glucose
disappearance (GRd), the glucose turnover rate, which equaled to GRa
and GRd in mg/min, was calculated by dividing the [3-3H]-glucose
infusion rate (dpm/mg) by the steady-state value of glucose specific
activity (dpm/mg). Under these conditions, the glucose turnover rate
was equal to the sum of the rates of exogenous infused glucose and
of hepatic glucose production (HGP). From this equation the rate of
HGP was calculated. Since urinary glucose loss was not present,
peripheral glucose uptake (PGU) was taken as glucose turnover rate
which equaled to exogenous glucose infusion rate plus rate of HGP.
Statistical analysis
Data were presented with mean±SD. Comparisons between
groups were made by the two-tailed Student’s t test. All
statistical analyses were performed using SPSS.
RESULTS
General characteristics of animals
There were no differences in the mean body mass between
control and lipid-infusion rats. Basic plasma concentrations of
glucose, insulin, and free fatty acids (FFA) were similar in the two
groups (Table 1).
Table 1 General
characteristics of control and lipid-infusion rats (n = 12,
mean±SE)
| Group |
Control |
Lipid-infusion |
| Body
mass (g) |
279±19 |
286±17 |
| Fasting
blood glucose (mmol/L) |
5.2±0.1 |
5.1±0.2 |
| Fasting
plasma insulin (mU/L) |
30.3±2.4 |
27.9±2.2 |
| Fasting
free fatty acids (mmol/L) |
672.5±92.2 |
741.9±50.6 |
Effects
of surgery
As expected, following surgery catheterized animals lost
significant weight during the initial 24-h period, averaged 18±3 g.
Following this catabolic stage they appeared well and normally
active. Food intake was qualitatively normal, and average daily
weight gain (-5g) closely resembled that of normal littermates that
did not undergo surgery.
Figure 1(PDF)
Time course of glucose infusion rate during hyperin-
sulinemic euglycemic clamping.
Figure 2(PDF)
Steady-state hepatic glucose production, glucose
disappearance rate, glucose infusion rate during
hyperinsulinaemic-euglycaemic clamp studies in control and
lipid-infused rats. bP<0.01, vs control.
Insulin
clamp studies
A lipid infusion of 4 h at a rate of 1 mL/h was used to
examine the effect on plasma insulin, FFA, peripheral glucose uptake
and hepatic glucose production. During the
euglycemic-hyperinsulinemic clamps blood glucose concentrations
remained constant compared to the basal levels and were not
different between control and lipid infusion studies. Plasma insulin
concentrations increased similarly to -100 mU/L in both studies
(Table 2). The coefficients of variation in plasma glucose and
insulin levels were 4.8 and 7.6 % , respectively, in all studies. In
the control study the plasma concentration of FFAs dropped by -65%
once the euglycemic clamp was started, but it increased
approximately fourfold (from 741.9±50.6 to 2346.4±238.5 mmol/L,
P<0.01) within 120 min of hyperinsulinemic clamp in the
lipid - infused group (Table 2). The time course of the glucose
infusion rate (GIR) during insulin clamp is shown in Figure 1. The
GIR in lipid infusion rats, compared to control rats, was
significantly reduced (200-240 min average: lipid infusion; 12.6±1.5
vs control; 34.0±1.6 mg/kg.min, P<0.01, Table 2 and
Figure 2), declining to -35% of the corresponding control values
during the last time of the clamp (240 min: lipid infusion; 12.0±1.9
vs control; 34.7±1.7 mg/kg.min, P<0.0001, Figure 1).
After a 14-h fast there was no significant difference in HGP between
the two groups (19.0±4.5 vs 18.7±3.0 mg/kg.min in control and
lipid-infused rats, respectively). At the end of
hyperinsulinemic-euglycemic clamp study, the HGP in control rats was
significantly suppressed (88%) from 19.0±4.5 (basal) to 2.3±0.9
mg/kg.min (P<0.01, Table 2). The suppressive effect of
insulin on HGP was significantly blunted in lipid-infused rats
(180-240 min: lipid infusion; from 18.7±3.0 to 23.2±3.1 mg/kg.min P<0.05,
Table 2). The time courses of HGP for controls and lipid-infused
rats are shown in Table 2. During the clamp, the GRd was significant
increased compared with basal values. Although the GRd had no
significant difference between the two groups, there was a slight
decrease in lipid-infused rats compared with controls (Table 2).
Figure 2 shows the average values of HGP, GRd and GIR during the
clamp in control and lipid-infused
rats.
Table
2 Plasma parameters
and glucose turnover data in control and lipid-infusion rats during
euglycemic hyperinsulinemic claming (mean±SE)
| Group |
Basal |
Clamping
time (min) |
| 120 |
200 |
220 |
230 |
240 |
|
Glucose
(mmol/L) |
| Control
(n = 12) |
5.2±0.1 |
5.3±0.1 |
5.0±0.2 |
5.2±0.1 |
5.2±0.2 |
5.4±0.2 |
| Lipid
(n = 12) |
5.1±0.2 |
5.3±0.2 |
5.2±0.2 |
5.3±0.2 |
5.5±0.2 |
5.5±0.2 |
|
FFA
(mmol/L) |
| Control
(n = 12) |
672.5±92.2 |
642.3±104.8 |
240.6±20.9 |
221.3±27.4 |
201.8±29.8 |
183.1±21.4 |
| Lipid
(n = 12) |
741.9±50.6 |
2807.2±348.8bd |
3086.9±495.2bd |
2518.8±416.7bd |
2241.2±431.0bd |
2346.4±238.5bd |
|
Insulin
(mU/L) |
| Control
(n = 12) |
30.3±2.4 |
34.7±6.4 |
89.5±7.9 |
90.7±7.4 |
88.3±5.9 |
101.3±6.3 |
| Lipid
(n = 12) |
27.9±2.2 |
31.4±3.3 |
84.2±6.7 |
93.3±8.9 |
103.5±16.3 |
104.5±14.8 |
| GIR
(mg/kg.min) |
| Controls
(n=12) |
0 |
|
32.8±1.7 |
34.4±1.6 |
34.4±1.6 |
34.7±1.7 |
| Lipid
(n = 12) |
0 |
|
12.7±1.3b |
12.9±1.6b |
12.9±1.8b |
12.0±1.9b |
| GRd
(mg/kg·min) |
| Controls
(n = 12) |
|
19.0±4.5 |
43.1±6.1d |
40.1±6.7d |
35.5±6.8d |
33.2±3.2d |
| Lipid
(n = 12) |
|
18.7±3.0 |
36.3±3.1d |
38.3±4.4d |
32.4±4.5d |
35.1±3.9d |
| HGP
(mg/kg·min) |
| Controls
(n = 12) |
|
19.0±4.5 |
14.2±4.9c |
10.2±4.4d |
3.1±1.9d |
2.3±0.9d |
| Lipid
(n = 12) |
|
18.7±3.0 |
23.4±4.3bc |
25.3±3.7bd |
21.5±3.5b |
23.2±3.1bd |
FFA:
free fatty acids. GIR: glucose infusion rate. GRd: glucose
disappearance rate. HGP: hepatic glucose production. aP<0.05;
bP<0.01
vs control; cP<0.05;
dP<0.01
vs Basal. The basal values of HGP were determined at 120 min.
DISCUSSION
Obesity is associated with insulin resistance and
hyperinsulinemia, two important cardiovascular risk factors[11].
What remains uncertain is how obesity produces insulin resistance
and hyperinsulinemia. It has recently become clear, however, that
FFA plays a pivotal role in this process. Although there are a
number of studies on this subject, the precise mechanisms of FFA
effect on insulin action are not completely understood. In the
present study we examined the effect of a 4-h lipid infusion on In
vivo insulin action in conscious rats, by the
hyperinsulinaemic-euglycaemic clamp technique, in combination with a
continuous infusion of [3-3H]-glucose. This method is
considered to be the most suitable for the measurement of In vivo
insulin. In our hyperinsulinemic clamping, insulin infusion
increased plasma insulin levels to an approximate three-fold over
basal insulin level, whereas blood glucose was clamped at
approximately 5.3 mmol/L in the control and lipid infusion groups.
Plasma FFA concentrations were suppressed by approximately -65%
during clamps in the control group. But in lipid infusion rats, the
FFA levels had a rapid increase more than 3.8-fold over basal levels
and the increase was maintained to the end of hyperinsulinemic
clamp, suggesting that lipid infusion impaired the antilipolytic
action of insulin and promoted the release of fatty acids from
adipocytes or infused lipid. It is widely known that elevated FFA
levels could exert a deleterious effect on insulin’s overall
actions, and this has been demonstrated in both animals and humans[12].
The mechanisms underlying FFA-induced insulin resistance are not
very clear, but elevated plasma levels of FFA produced at least two
distinct biochemical defects: inhibition of insulin stimulated
glucose transport and/or phosphorylation, and inhibition of muscle
glycogen systhase activity[13].
In the attempt to better our understanding of the
pathophysiology of lipid-induced insulin resistance, we examined the
effect of lipid infusions on HGP. We found that HGP was suppressed
by -88% in the controls during hyperinsulinaemic- euglycaemic clamp,
suggesting the impact of insulin on the suppression of endogenous
glucose production. However, HGP was not significantly suppressed in
lipid-infused rats. Thus, lipid infusion elevated the levels of
circulating FFA and elevated FFA levels interfered with insulin’s
ability to inhibit hepatic glucose production. The increased hepatic
glucose production in response to lipid infusion suggested that an
experimental elevation of circulating FFA levels could lead to
hepatic insulin resistance. On the other hand, during insulin clamp
glucose infusion rates (GIR), compared to control rats, were
significantly reduced to -35% of the corresponding control values
during the last time of the clamp. At clamping steady state,
peripheral glucose uptake was equal to the sum of the rates of
exogenous infused glucose (GIR) and hepatic glucose production (HGP).
If HGP was completely suppressed, peripheral glucose uptake would
equal to GIR (in controls). But, HGP was not significantly
suppressed in lipid-infused rats, so peripheral glucose uptake was
equal to GRa, which equaled to HGP plus GIR. Total glucose uptake is
the sum of glucose removal by insulin-dependent as well as
insulin-independent tissues. In the present study we found there was
a slight decrease in GRa in lipid infusion groups, although the data
did not reach statistical significance. Nonetheless, the trend is
obvious since the brain and splanchnic tissues use glucose in an
insulin-independent manner, roughly 750 g/L of total glucose
utilization is considered to be insulin-independent in fasting
condition. Thus, this might indicate that 4 h of lipid infusion
induced a partial defect in insulin-stimulated peripheral glucose
uptake, consistent with previous In vivo studies by Kim et
al.[14]. Considering the absence of HGP-suppressing
effect of insulin under lipid infusion condition, we concluded that
an experimental elevation of circulating FFA levels by lipid/heparin
infusions could lead to peripheral and hepatic insulin resistance.
The mechanism of lipid-induced insulin resistance remains poorly
understood and may involve different IRS-1-associated PI3-kinase
activation[15], and the activity of IkB
kinase-b
(Ikk-b,
a known serine kinase)[14,16].
In
summary, the current studies showed that infusion of lipid emulsions
with heparin to acutely raise plasma fatty acid concentrations could
impaire the ability of insulin to stimulate overall body glucose
disposal and also interfered with insulin’s ability to inhibit
hepatic glucose production. Thus, we propose that a sustained
increase in circulating FFA causes a hepatic insulin resistance, and
may lead to a partial defect in insulin-stimulated peripheral
glucose uptake, which can be attributed to lipotoxic effect on
insulin action.
REFERENCES
1
Reaven GM. Role of insulin resistance in human disease.
Diabetes 1988; 37: 1595-1607
2
Boden G. Role of fatty acids in the pathogenesis of insulin
resistance and NIDDM. Diabetes 1997; 46: 3-10
3
Randle PJ, Garland PB, Newsholme EA, Hales CN. The glucose
fatty acid cycle in obesity and maturity onset diabetes
mellitus. Ann N Y Acad Sci 1965; 131:
324-333
4
Randle PJ, Garland PB, Hales CN, Newsholme EA.The glucose
fatty-acid cycle: its role in insulin sensitivity and the
metabolic disturbances of diabetes
mellitus. Lancet 1963; 1: 785-789
5
Boden G, Jadali F, White J, Liang Y, Mozzdi M, Chen X,
Coleman E, Smith C. Effects of fat on insulin-stimulated
carbohydrate metabolism in normal
men. J Clin Invest 1991; 88: 960-966
6
Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction
between glucose and free fatty acid metabolism in human
skeletal muscle. J Clin Invest 1993;
92: 91-98
7
Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL,
Cline GW, Shulman GI. Mechanism of free fatty acid-induced
insulin resistance in humans. J Clin
Invest 1996; 97: 2859-2865
8
Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline
GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL,
Petersen KF, Shulman GI. Effects of
free fatty acids on glucose transport and IRS-1-associated
phosphatidylinositol
3-kinase activity. J Clin Invest
1999; 103: 253-259
9
Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D,
Goodyear LJ, Kraegen EW, White MF, Shulman GI. Free fatty
acid-induced insulin resistance is
associated with activation of protein kinase C theta and alterations
in the insulin
signaling cascade. Diabetes 1999; 48:
1270-1274
10 Koopmans SJ, van
Mansfeld ADM, Jansz HS, Krans HMJ, Radder JK, Frolich M, de Boer SF,
Kreutter DK, Andrews GC,
Maassen JA. Amylin-induced In vivo
insulin resistance in conscious rats: the liver is more sensitive to
amylin than
peripheral tissues. Diabetologia
1991; 34: 218-224
11 Fontbonne AM, Eschwege
EM. Insulin and cardiovascular disease. Paris prospective study.
Diabetes Care
1991; 14: 461-469
12
Hevener AL, Reichart D, Janez A, Olefsky J. Thiazolidinedione
treatment prevents free fatty acid-induced insulin
resistance in male wistar rats.
Diabetes 2001; 50: 2316-2322
13 Boden G. Free fatty
acids (FFA), a link between obesity and insulin resistance. Front
Biosci 1998; 15: d169-175
14 Kim JK, Kim YJ,
Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret
P, Shoelson SE, Shulman GI.
Prevention of fat-induced insulin
resistance by salicylate. J Clin Invest 2001; 108: 437-446
15 Yu C, Chen Y, Cline GW,
Zhang DY, Zong HH, Wang YL, Bergeron R, Kim JK, Cushman SW, Cooney
GJ, Atcheson B, White
MF, Kraegen EW, Shulman GI. Mechanism
by which fatty acids inhibit insulin activation of insulin receptor
substrate-1
(IRS-1)-associated
phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;
277: 50230-50236
16 Yin MJ, Yamamoto Y,
Gaynor RB. The anti-inflammatory agents aspirin and salicylate
inhibit the activity of IkB
kinase-b.
Nature 1998; 396: 77-80
Edited
by
Zhang
JZ and Wang XL Proofread
by Xu FM
| |